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Summary This is a study of 5595 head and neck cancer patients treated during 1987-89 at TMH, Mumbai. The study included 1970 oral
cancers (ICD 140-145), 1495 oropharyngeal cancers (ICD 1410, 1453, 146), 1255 hypopharyngeal cancers (ICD 148), 125 nasopharyngeal
cancers (ICD 147) and 750 laryngeal cancers (ICD 161). The clinical extent of disease at presentation was based on TNM group staging
(UICC 1978). For the majority of sites, patients attended the hospital during stage IlIl and stage IV of the disease; the only exception was for
cancers ofthe lower lip, anteriortongue and vocal cord when between 46.2% and 56.5% of patients with localized cancer (stage and 11) were
seen. Generally, surgery either alone or with radiation has been administered for oral cancer patients whereas radiation either alone or in
combination with chemotherapy was administered for other head and neck sites. The overall 5-year survival rate was in the range of 20-43%
for oral cancer, 8-25% for pharyngeal cancers and 25-62% for laryngeal cancer. The 5-year relative survival rates were more or less in
agreement with the results published by the Eurocare study for head and neck cancers. The importance of primary prevention in head and
neck cancer is stressed.
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Incidence data that are available from six metropolitan cities and
one rural registry in India indicate that head and neck cancer is a
common problem there (IARC, 1992). Many epidemiological
studies carried out in the sub-continent have shown the association
of tobacco, alcohol and some dietary items with head and neck
cancer. Although primary prevention may be the ideal choice for
the control ofhead and neck cancer, secondary prevention through
therapeutic intervention has an equal and important role to play.
Management of head and neck cancer in a high-risk population
and its response to conventional treatment and survival have not
been reported in detail. The aim is to analyse individual sites of
head and neck cancer according to stage of the disease, primary
treatment and other prognostic factors for 5-year survival.
Comparison is also made with survival in European countries.
PATIENTS AND METHODS
This is aretrospective analysis of5595 eligible head and neckcancer
patients who were diagnosed and treated at Tata Memorial Hospital,
Mumbai, during the period 1987-89. The eligibility criteria for
inclusion ofpatients in the study were: (1) no prior cancer-directed
treatment at the time of registration; (2) histologically confirmed
epithelial cancer; (3) treatment with chemotherapy together with
surgery or radiation but not as the only treatment; and (4) at least 50
cases in each subsite ofhead and neck cancer. The excluded subsites
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were upper lip (five cases), commissure of lip (six cases), tongue
NOS (not otherwise specified) (one case), salivary gland (39 cases),
palate NOS (two cases) and subglottic larynx (seven cases).
Information on age, sex, date of diagnosis, method of diagnosis,
primary site (ICD 1978), secondary site, if available, histology of
primary and/or secondary tumour, TNM staging (UICC, 1978) and
primary treatment given within 6 months ofdiagnosis were obtained
from the database maintained by the hospital cancer registry. The
clinical extentofthediseaseforheadandneckcancercases was clas-
sified intofourstages, viz. stage IcomprisingTINOMOstatus, stage II
comprising T2NoMO, stage IIIcomprising T3NoMO, T3N, MO,T, N
MO and T2 N MO and stage IV comprising T4NoMO, T4 N MO, and
anyT, N2 orN3MOand any Tany NM,. Periodic updatingoffollow-
up information was carried out eitherby scrutiny ofmedical records
ofattending patients or by postal enquiry responses. In some cases,
follow-up information was alsoobtainedby scrutiny ofdeathrecords
maintained by the Municipal Corporation of the City, of life insur-
ance claims and ofrecords from terminal care centres/pain clinic in
the city. The study was closed on 31 March 1996, and data available
up to that time were used for the survival analyses. In this study of
5595 patients, 2435 patients (43%) were known to have died and
1128 patients (20%) were known to be alive at the end of 5 years
from their date of diagnosis. For the remaining 2032 patients, 267
patients (4.7%) hadfollow-up information forbetween 3 and 5 years,
1384 patients (24.7%), categorized as non-responders, had less than
3 years offollow-up information and 381 patients (6.8%) hadincom-
plete addresses (untraced cases). Complete follow-up information
was 68% for the laryngeal group, 65% for oral cancer, 64% for the
oropharyngeal and nasopharyngeal group and 60% for the hypo-
pharyngeal group. At the end of 1 year, the equivalent figures were
about 84% for laryngeal cancer and 70-80% for the other groups.
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Table 1 Clinical characteristics and observed survival rates (%) for oral cancers 1987-89
Site Lower lip Ant. tongue L. alvelous U. alvelous Floor mouth Buccal mucosa Hard palate Retromolar
(ICD 9) (1401) (1411-14) (1431) (1430) (1449) (1450-51) (1452) (1456)
Number of cases 62 522 340 71 88 728 90 69
Sex ratio 3.1:1 2.3:1 2.3:1 1.7:1 7.8:1 2.2:1 3.3:1 2.8:1
Average age ± s.d. (years) 50.7 ± 13.6 49.4 ± 11.9 52.2 ± 10.5 52.7 ± 13.6 51.1 ± 9.4 50.8 + 11.7 54.1 ± 12.5 53.2 ± 9.2
Stage (%)
22.6 20.9 1.2 2.8 5.7 6.2 1.1 1.5
11 32.3 25.3 6.7 19.7 18.2 20.0 26.6 13.0
III 14.5 31.0 9.1 47.9 13.6 19.5 36.6 30.4
IV 29.0 21.3 81.2 22.5 58.0 52.1 17.9 53.6
NOS 1.6 1.5 1.8 7.1 4.5 2.2 17.8 1.5
Treatment summary (%)
Surgery 83.9 50.4 48.8 32.4 23.9 42.9 18.9 23.2
Radiation 1.6 18.8 6.5 21.1 36.4 19.1 56.7 39.1
Surgery + radiation 12.9 22.4 35.3 39.4 28.4 28.7 20.0 24.6
Othersa 1.6 8.4 9.4 7.1 11.3 9.3 4.4 13.1
Survival with Cl
1 year 61 (49-73) 55 (51-59) 62 (57-68) 46 (35-58) 47 (36-57) 61 (57-64) 51 (41-61) 56 (45-68)
3 years 48 (36-60) 36 (32-40) 35 (30-40) 21 (12-31) 23 (14-31) 39 (35-42) 34 (25-44) 29 (18-40)
5 years 43 (31-56) 33 (29-37) 31 (26-36) 20 (10-29) 21 (13-30) 34 (31-37) 31 (21-40) 25 (14-35)
Median survival (in months) 33 17 19 12 12 20 16 17
aincludes chemotherapy either with surgery or with radiation or with both. Cl, 95% confidence interval; NOS, not otherwise specified.
Table 2 Clinical characteristics and observed survival rates (%) for pharyngeal and laryngeal cancers 1987-89
Site Base Soft Tonsil Oropharynx Post Pyriform Hypopharynx Vocal cord Supra Nasopharynx
tongue palate NOS cricoid fossa NOS glottic
(ICD 9) (1410) (1453) (1460) (1461-69) (1480) (1481) (1482-89) (1610) (1611) (1470-79)
Number of cases 818 142 346 189 171 1000 84 259 491 125
Sex ratio 11.4:1 7.4:1 8.6:1 6.3:1 0.9:1 12.3:1 3.4:1 17.5:1 7.8:1 4.2:1
Average age ± sd (years) 55.0±10.6 56.2±10.5 55.9±10.9 56.6±10.5 49.9±13.9 55.5±10.4 53.6±13.5 56.0±11.2 55.2±10.5 38.2±18.2
Stage distribution (%)
1 0.7 6.3 2.0 2.1 1.2 0.1 1.2 51.7 1.8 0.8
11 10.1 25.4 8.1 13.2 15.2 8.7 11.9 15.4 11.4 2.4
III 46.2 38.7 50.6 55.0 50.9 52.9 60.7 20.1 56.0 15.2
IV 41.7 27.5 37.3 28.0 29.8 37.0 25.0 9.7 25.7 76.8
NOS 1.3 2.1 2.0 1.7 2.9 1.3 1.2 3.1 5.1 4.8
Treatment summary (%)
Surgery 0.7 2.1 0.3 0 10.5 3.4 2.4 11.2 2.9 0
Radiation 86.2 81.7 87.3 90 74.3 79.1 84.5 74.9 85.7 50.4
Surgery + radiation 3.2 6.3 2.9 2.1 11.1 12.9 4.8 13.1 8.6 4.8
Othersa 9.9 9.9 9.5 7.9 4.1 4.6 8.3 0.8 2.8 44.8
Survival with Cl
1 year 43 (39-46) 58 (49-66) 44 (39-49) 45 (38-52) 34 (26-40) 48 (44-51) 39 (29-50) 82 (77-87) 54 (41-58) 50 (42-59)
3 years 19 (16-21) 33 (25-41) 15 (11-19) 20 (14-26) 16 (11-22) 22 (19-24) 13 (6-20) 65 (59-71) 28 (24-32) 27 (19-35)
5 years 15 (12-17) 25 (17-32) 13 (9-16) 14 (8-19) 13 (8-18) 17 (15-20) 8 (2-14) 62 (56-68) 25 (21-29) 21 (14-28)
Median survival (in months) 10 18 11 11 7 12 9 14 13
aincludes chemotherapy either with surgery or with radiation or with both. bNot reached. Cl, 95% confidence interval; NOS, not otherwise specified.
The number of untraced cases was around 7% for all sites, except
laryngeal cancerforwhichthefigure was3.7%; similarly, thepropor-
tion ofnon-responders was around 25% for all sites except forlaryn-
geal cancer (21.6%). The proportion of both untraced and
non-responding patients who had stage HII and stage IV cancers at
theirfirst visit tohospital was between 70% and 92% in the different
site groups, and thesepatients were considered unsuitable for further
treatment, except for pain relief or symptomatic treatment. Patients
with less than 3 years of follow-up were considered as being
deceased, and survival information availableup to thattime was used
for analysis purposes. The Kaplan-Meier method was used to esti-
mate survival ratesfor 1,3 and5 years andalsotoassesscertainprog-
nostic factorsconsideredinthestudy. As 70% ofthepatientsattended
hospital from Maharashtra state, the life table for Maharashtra State,
published by the Government ofIndia for the period 1986-90 (RGI,
1994), was used to estimate the relative survival rates.
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Table 3 Five-year observed survival rates (in %) for oral cavity, pharyngeal and laryngeal cancers by treatment
Site Surgery Radiation Surgery Surgery Radiation Surgery
+ radiation + chemotherapy + chemotherapy + radiation
+ chemotherapy
Oral cavity
Lower lip 47.8 Oa 25 - Oa
Anterior tongue 47.8 13.2 22.0 33.3 11.1 27.2
Lower alveolus 34.4 13.6 28.9 45.0 20.0 14.3
Upper alveolus 30.4 13.3 17.1 - Oa Oa
Floor mouth 42.9 3.1 36.0 - - Oa
Buccal mucosa 46.4 23.3 27.9 30.7 6.7 26.3
Hard palate 58.8 19.6 38.9 - 25.0
Retromolar 37.5 14.8 41.2 Oa Oa Oa
Oropharynx
Base tongue 66.7 15.3 19.2 Oa 6.0 Oa
Soft palate 66.7 24.2 55.6 - - Oa
Tonsil Oa 13.9 20.0 - 3.3 Oa
Oropharynx NOS - 14.0 Oa - 7.1 100a
Hypopharynx
Post-cricoid 11.1 14.8 7.9 - 0 Oa
Pyriform fossa 14.1 15.6 32.5 Oa 7 100a
Hypopharynx NOS Oa 8.5 Oa _ -
Nasopharynx - 12.7 44.4 - 28.5 Oa
Larynx
Vocal cord 72.4 62.1 51.7 - 50.0
Supraglottic 28.6 25.2 48.0 Oa 25.0 Oa
aEstimate based on five or less cases. -, No patient.
Table 4 Five-year relative survival rates (%) according to sex and TNM group staging for head and neck cancers 1987-89
Five-year relative survival (%)
Sex Stage
M F I II IlIl IV
Oral Cavity
Lower lip 51.3 35.6 69.8 54.0 60.3 12.7
Anterior tongue 35.5 35.8 63.6 49.8 22.8 11.2
Lower alveolus 36.2 29.5 56.0 65.6 41.7 30.0
Upper alveolus 24.8 16.5 Oa 31.2 19.4 13.5
Floor mouth 20.8 42.6 65.2 33.7 26.6 14.9
Buccal mucosa 39.4 32.1 67.4 60.6 25.3 25.0
Hard palate 35.3 30.4 100 49.6 23.3 7.0
Retromolar 30.6 18.0 1ooa 36.7 31.3 17.6
Oropharynx
Base tongue 16.64 16.6 89.94 35.8 21.2 4.94
Soft palate 26.2 38.8 50.2 39.6 27.9 8.77
Tonsil 14.95 12.1 64.1 30.8 14.37 8.3
Oropharynx NOS 15.3 15.7 Oa 50.8 10.3 8.3
Hypopharynx
Post-cricoid 15.5 12.7 Oa 36.4 13.5 2.1
Pyriform fossa 19.9 17.25 Oa 44.6 21.8 10.8
Hypopharynx NOS 8.6 11.3 100a 0 10.7 5.2
Nasopharynx 21.6 23.7 1ooa 35.5 22.7 21.7
Larynx
Vocal cord 70.45 60.36 78.9 60.5 55.6 52.0
Supraglottic 27.2 38.0 74.0 61.7 28.7 9.1
aEstimate based on five or less cases.
RESULTS
The clinical characteristics, TNM staging, treatment summaries
and observed survival rates for 1970 oral cancer cases are
presented in Table 1. The average age ofpatients ranged from 49.4
years for anteriortongue cancerto 54.1 years in hardpalate cancer.
The distribution ofTNM staging among eight sites oforal cancers
showed that except for lower lip (54.9%) and anterior tongue
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cancer (46.2%), for most of the sites, patients with stage I and
stage II disease together accounted for between 7.9%, for lower
alveolus cancers, and 27.7%, for hard palate cancers.
Management of oral cancer depends largely on the stage of the
disease. In our series, surgery alone or radiotherapy alone or their
combination remained as the primary treatment. The 'other' treat-
ment category mostly included the combination of chemotherapy
with either surgery or radiation or both in the management oforal
cancer. The 5-year observed survival rate varied between 20% for
the upper alveolus and 43% for lower lip cancers.
The comparable data for pharyngeal and laryngeal cancers are
presented in Table 2. In contrast to most of the cancers, a marked
predominance of men was seen for all the sites except for post-
cricoid cancers, for which a female excess was observed. The
average age of the patients varied between 38.2 years for cancer of
the nasopharynx and 56.6 years for oropharyngeal cancer. The base
of the tongue (818 cases) and pyriform fossa (1000 cases) were the
two predominant sites observed in this group. The TNM stage distri-
bution of individual sites indicated that 80-90% of cases presented
with stage III or IV malignancies, the only exception being forvocal
cord cancers for which the percentage was much lower (30%). In
view ofthis, for most ofthe patients, radiotherapy was administered
as theonly treatment. In the case ofnasopharyngeal cancer, radiation
along with chemotherapy was administered for about 44.8% of the
patients and the 5-year observed survival rate for vocal cord cancer
was about 62%. For all other sites, the 5-year survival rate ranged
between 8%, for hypopharyngeal cancers, and 25%, for both soft
palate and supraglottic cancers.
The 5-year observed survival rates according to primary treat-
ment for the eighteen sites ofhead and neck cancer considered are
presented in Table 3. Surgery, when used alone forthe treatment of
oral cancer, was followed by a 30-58% 5-year survival ofpatients.
The 5-year survival for radiotherapy alone in oral and pharyngeal
cancers in our study was in the range of3-24%. Vocal cord cancer,
when treated by radiotherapy alone, showed a 62% 5-year survival
rate. The certain combinations of treatment showed good
percentage 5-year survival rates for particular sites, namely
nasopharynx, lower alveolus and supra glottis.
The 5-year relative survival rates by sex and TNM stage for all
the 18 sites of head and neck cancer are presented in Table 4.
Women showed better5-year survival rates for cancers ofthe floor
mouth (M, 20.8%; F, 42.6%), softpalate (M, 26.2%; F, 38.8%) and
hypopharynx (M, 8.6%; F, 11.3%) than men. The stage of the
disease is known to be an important prognostic factor. With the
increase in the stage of disease, there has been a corresponding
decrease in survival. Although few patients were observed with
Table 5 Five-year relative survival rates (%) for the Eurocare study (A) and the Tata Memorial Hospital Study (B)
(A) (B)
Eurocare study' Hospital study
Study period 1978-85 Study period 1987-89
Country (%)
Site (ICD) Cases 5-year survival Highest Lowest Site (ICD) Cases 5-year survival
Tongue (141) 3299 39 Scotland (46) Poland (15) Tongueb 1341 24.02
Finland (45) France (28) Base tongue 818 16.6
Switzerland (43) The Netherlands (28) Antenor tongue 522 35.8
Oral cavity (143-145) 4382 46 The Netherlands (62) Estonia (33) Oral cavityc 1529 33.2
Finland (51) Poland (33) Upperalveolus 71 21.7
England (48) Italy (38) Lower alveolus 340 34.3
Floor mouth 88 23.4
Buccal mucosa 728 37.3
Hard palate 90 34.4
Soft palate 142 27.6
Retromolar 69 27.0
Oropharynx (146) 2457 33 The Netherlands (45) Italy (23) Oropharynx 535 14.7
Poland (44) Scotland (23) Tonsil 346 14.6
England (36) Estonia (27) Oropharynx 189 15.4
Nasopharynx (147) 1078 38 Switzerland (84) Estonia (16) Nasopharynx 125 22.2
Italy (55) Scotland (24)
Finland (51) Poland (28)
Hypopharynx (148) 2199 19 The Netherlands (36) Poland (7) Hypopharynx 1255 18.0
Scotland (24) Finland (8) Post-cricoid 171 14.3
Estonia (23) Switzerland (14) Pyriform fossa 1000 19.6
Hypopharynx 84 9.2
Larynx (161) 10 612 57 The Netherlands (73) France (47) Larynxd 757 41.8
Scotland (64) Estonia (50) Vocal cord 259 68.0
England (63) Denmark (60) Supraglottis 491 28.0
aSource, IARC (1995). bincludes tongue NOS (one case). cincludes palate NOS (one case). dincludes subglottis (seven cases).
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stage I cancer, the 5-year relative survival rates were in the range
56-100% for oral cancers (except forthe upper alveolus), 50-90%
for oropharyngeal cancer, 100% for nasopharyngeal cancer and
74-79% for laryngeal cancer. This indicates the effectiveness of
conventional treatment in the early stage ofthe disease.
DISCUSSION
This is a retrospective analysis of 5595 head and neck cancer
patients treated during the period 1987-89. Some other sites,
namely upper lip, nasal sinus, max antrum and salivary glands,
were not included mainly because of the small number of cases
and/or because non-epithelial cancers were prevalent among these
sites. Management ofhead and neck cancer depends largely on the
size of the tumour, nodal status and histological variety. For oral
cancer, surgery either alone or in combination with radiation had
been the modality of treatment. For oropharyngeal and hypo-
pharyngeal cancers, radiation therapy had been administered,
largely because of the advanced stage of the disease at presenta-
tion. In the case ofnasopharyngeal cancer, chemotherapy hadbeen
administered along with radiation therapy in a large percentage of
cases. Laser surgery had been performed for a few selected sites of
head and neck cancer but was not identified separately in our
analyses. The sequence of treatments, when more than one was
administered, has not been considered. In addition, no attempt has
been made to identify the nature of surgery or level of radiation
dose or chemotherapy schedule in evaluating the efficacy of the
treatment. Furthermore, statistical comparison has not been made
of the efficacy of different treatments from the data presented in
Table 3, mainly because of the likehood of selection bias and of
patients' reluctance to undergo surgery, which often would have
involved reconstruction and a long stay in hospital. In this study,
we have not looked at disease-free survival to indicate the efficacy
of primary treatment for head and neck cancer, and many of the
patients during the course of follow-up may have received treat-
ment for recurrences or for metastatic disease that subsequently
prolonged their survival; in which case, primary treatment alone
cannot be considered to have cured the disease.
In general, among the patients considered for the study, 25%
came from the city of Mumbai, about 45% from the State of
Maharashtra and the rest from various states in India. Canceris not
a notifiable disease and vital statistics records for various states in
India do not provide the cause ofdeath. Patients' follow-up status
was ascertained mainly through postal inquiry. Non-availability of
complete addresses for the patients and failure to respond to our
postal inquiry are the factors responsible for a significant
percentage of loss during the first year of follow-up in our study.
However, the assumption that patients lost to follow-up by the end
of3 years were dead is probably reasonable given thatthe majority
had stage III or IV cancers the last time that they were seen.
The results of the present study are compared in Table 5 with
those from the Eurocare study (IARC, 1995). In our study, the
results are available for subsites of all head and neck cancers
(fourth digit ICD), whereas in the Eurocare study some sites are
only available by three-digit site (e.g. 141 - tongue) or by combi-
nations of three-digit codes, as in the case of oral cavity (ICD
143-145). To facilitate comparisons, grouped results are also
given for the Indian data in Table 5, including here the small
number of subsites that were excluded from the main body of the
study. Although the 5-year survival rates show distinct variation
between the sites and subsites, the results obtained in our study are
reasonably similar to those observed in the Eurocare study. The
importance ofreporting survival by subsites is clearly brought out
in the case oftongue, oral cavity and pharynx.
Other studies have been reported in the literature either for all
sites ofhead and neck cancer individually or by groups (Flores et
al, 1986; Rice and Spiro, 1989; Steinhart and Leinsassaer, 1992;
Cole et al, 1994; Sagar et al, 1994; Mishra et al, 1996; Mohanti et
al, 1996; Grau et al, 1997). The direct comparison of our study
results with those reported in the literature has to be done with
caution, however, especially as the majority of studies report
observed rather than relative survival rates.
Head and neck cancer constitute about one-third ofall cancer seen
atTataMemorialHospital, Mumbai. TheTNMstagingdistributionof
head and neck cancer in the hospital over the years indicates that a
highpercentageofcases were seen atanadvanced stageofthedisease
(HCR, 1996). The present study also showed a large percentage of
patients with advanced disease at presentation. This, in turn, is
reflected inthe low survival rates observed for some sites ofheadand
neck cancerin comparison with those seen in European countries.
Many epidemiological studies carried out from high-risk and
low-risk populations have indicated the association of tobacco,
alcohol, the chewing of betel quid and some dietary items with
head and neck cancer. Eventually, head and neck cancer control
will best be achieved through primary prevention, although earlier
diagnosis should also be an aim.
ACKNOWLEDGEMENTS
The authors wish to thankthe staffofthe Hospital CancerRegistry
for their help and assistance and Miss Hilda Sequeira for typing
the manuscript.
REFERENCES
Cole DA, Patel PM, Matar JR, Kenady DE and Maruyama Y (1994) Floor ofthe
mouth cancer. Arch OtolaryngolHeadNeck Surg 120: 260-263
Flores AD, Dickson RI, Riding K and Coy P (1986) Cancer ofnasopharynx in
British Columbia. Am JClin Oncol 9: 281-291
Grau JJ, Cuchi A, Traserra J, Firvida JL, Arias C, Blanch JL and Estape J (1997)
Follow-up study in head and neck cancer: cure rate according to tumour
location and stage. Oncol Switzerland, Oncol 54: 38-42
HCR (1996) Hospital CancerRegistry. Desai PB, Rao DN, Rao RS and ShroffPD
(eds), Annual Reports 1984-94. Tata Memorial Hospital, Mumbai.
IARC (1992) CancerIncidence in Five Continents, Parkin DM, Muir CS, Whelan
SL, Gao YT, Ferlay J and Powell J (eds), Scientific Publication no. 120, Lyon.
IARC (1995) Survival ofCancerPatients in Europe. Scientific Publication no. 132,
International Agency forResearch on Cancer: Lyon
ICD (1978) International Classification ofDisease, 9th revision. WHO: Geneva
Mishra RC, Singh DN and Mishra TK (1996). Post operative radiotherapy in
carcinoma ofbuccal mucosa - a prospective randomized trial. EurJSurg
Oncol 22: 502-504
Mohanti BK, Tandon DA, Bahadur S, Rath GK, Tanwar RK, Lal P and Biswal BM
(1996) Results ofdefinitive radiotherapy inTI and T2 glottic cancer - Institute
ofRotary Hospital Experience. Australia Radiol 40: 287-290
RGI (1994) The Registrar General ofIndia, SRS-Based Abridged Life Table
1986-90, Occasional Paper no. 1.
Rice DH and Spiro RH (1989) Current Concepts in Head & Neck Cancer, American
Cancer Society: USA
Sagar SM, McKenna G and Nolan MC (1994) A clinical audit ofglottic cancer in
Nova Scotia: a paradigm for effectiveness research. Clin Oncol 6: 14-23
Steinhart H and Leinsassaer D (1992) Treatment and management ofsquamous cell
carcinoma ofthe floor mouth. Laryng Rhino Otol, 71: 556-560
UICC (1978) TNMClassification ofMalignant Tumours, Harmer MH (ed.),
International Union Against Cancer: Geneva
British Journal ofCancer(1998) 77(9), 1514-1518 e CancerResearch Campaign 1998